Latest News

December 06, 2017
Landmark study shows clot-busting drugs not recommended for most patients with secondary blood clots in the legs.
 
December 06, 2017
The rate of healthcare spending in the United States slowed down last year to levels previously seen between 2008-2015, driven by much slower growth in spending for retail prescription drugs, as well as hospital care and physician and clinical services. Private payers, Medicaid, and Medicare­ also saw lower rates of spending growth. 
December 06, 2017
A study published in the Journal of Managed Care & Specialty Pharmacy found that filgrastim and filgrastim-sndz were noninferior for the prevention of febrile neutropenia events that would require hospitalization. However, inferiority could not be established for serious adverse events.
December 06, 2017
Humana may also make an acquisition deal and UnitedHealth buys a unit of DaVita; a look at the FDA's expedited review programs; how a billing code discrepancy may have cost taxpayers up to $102 million in Medicare payments to hospitals.
December 06, 2017
WIth different societies and organizations releasing contrary guidelines around breast cancer screening, experience with past patients or friends and family members could influence physicians' decisions around when to start screening mammography.
December 05, 2017
For high-risk patients with hematological malignancies and febrile neutropenia, empirical antimicrobial therapy can be discontinued after 72 hours of apryexia and clinical recovery regardless of their neutrophil count, according to a study in The Lancet Hematology. The traditional approach of continuing the initial regimen of EAT in neutropenic patients with unexplained fever until neutrophil recovery could result in unnecessarily prolonged EAT.
 
December 05, 2017
A new study published Monday by scientists at the University of Massachusetts Medical School (UMMS) in Boston reports findings on a gene that is responsible for creating a protein that may help melanoma to grow and metastasize.
December 05, 2017
A systematic review of the FDA’s Adverse Event Reporting System (FAERS) found elevated reporting for both tofacitinib (Xeljanz) and ruxolitinib (Jakafi) for thromboembolic adverse events (AEs), suggesting the possibility of a class-wide issue with Janus kinase (JAK) inhibitors.
 
December 05, 2017
Semaglutide, Novo Nordisk’s once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist for type 2 diabetes (T2D), received FDA approval Tuesday, after beating its rival in a head-to-head trial and coming to the approval process with proof of cardiovascular benefits already in hand.
December 05, 2017
Senator Susan Collins, R-Maine, makes her tax bill vote contingent on more Obamacare funding; some states are setting up programs to recycle leftover drugs; and pregnant women deal with medication uncertainty.
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome to the new and improved AJMC.com, the premier managed markets network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!